卒中后治疗与结局的性别差异:纳入19000名参与者的汇总分析
该研究基于5项急性卒中随机对照试验的个体参与者数据,纳入19652例患者(女性占40%),采用随机效应荟萃分析评估性别在结局与管理上的差异。结果显示,女性缺血性卒中患者3-6个月生存率更高,但残疾可能性更高且生活质量更差;住院及院前管理存在性别差异,可能部分解释结局差异。
要点
- 女性缺血性卒中患者3-6个月生存率更高(OR 0.82,95%CI 0.70-0.97)。
- 女性残疾可能性更高(OR 1.20,95%CI 1.06-1.36),生活质量更差。
- 女性更少接受插管、发热治疗及ICU入住,院前抗血小板/降糖/降脂药处方率更低。
核心结论
- 女性缺血性卒中患者生存更好但残疾更重、生活质量更差,住院及院外管理差异可能部分解释结局差异。
研究设计与样本
- 汇总5项急性卒中随机对照试验的个体参与者数据,共19652例,女性7721例(40%),采用随机效应荟萃分析。
主要发现
- 女性缺血性卒中3-6个月生存更高(OR 0.82,95%CI 0.70-0.97),残疾可能性更高(OR 1.20,95%CI 1.06-1.36),生活质量更差(加权均数差 -0.07,95%CI -0.09至0.04)。
- 女性更可能入住急性卒中单元(OR 1.17,95%CI 1.01-1.34),但更少插管(OR 0.58,95%CI 0.36-0.93)、发热治疗(OR 0.82,95%CI 0.70-0.95)及入住ICU(OR 0.83,95%CI 0.74-0.93)。
- 院前用药方面,女性抗高血压药处方几率更高(OR 1.22,95%CI 1.13-1.31),抗血小板药(OR 0.86,95%CI 0.79-0.93)、降糖药(OR 0.86,95%CI 0.78-0.94)及降脂药(OR 0.85,95%CI 0.77-0.94)处方几率更低。
临床怎么用
- 临床应关注女性卒中患者残疾及生活质量问题,并审视住院及院前管理中的性别差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the sex differences in outcomes and management after stroke using a large sample with high-quality international trial data. METHODS: Individual participant data were obtained from 5 acute stroke randomized controlled trials. Data were obtained on demographics, medication use, in-hospital treatment, and functional outcome. Study-specific crude and adjusted models were used to estimate sex differences in outcomes and management, and then pooled using random-effects meta-analysis. RESULTS: There were 19,652 participants, of whom 7,721 (40%) were women. After multivariable adjustments, women with ischemic stroke had higher survival at 3-6 months (odds ratio [OR] 0.82, 95% confidence interval [CI] 0.70-0.97), higher likelihood of disability (OR 1.20, 95% CI 1.06-1.36), and worse quality of life (weighted mean difference -0.07, 95% CI -0.09 to 0.04). For management, women were more likely to be admitted to an acute stroke unit (OR 1.17, 95% CI 1.01-1.34), but less likely to be intubated (OR 0.58, 95% CI 0.36-0.93), treated for fever (OR 0.82, 95% CI 0.70-0.95), or admitted to an intensive care unit (OR 0.83, 95% CI 0.74-0.93). For preadmission medications, women had higher odds of being prescribed antihypertensive agents (OR 1.22, 95% CI 1.13-1.31) and lower odds of being prescribed antiplatelets (OR 0.86, 95% CI 0.79-0.93), glucose-lowering agents (OR 0.86, 95% CI 0.78-0.94), or lipid-lowering agents (OR 0.85, 95% CI 0.77-0.94). CONCLUSIONS: This analysis suggests that women who had ischemic stroke had better survival but were also more disabled and had poorer quality of life. Variations in hospital and out-of-hospital management may partly explain the disparities.
引用
- Carcel C, Wang X, Sandset EC, et al. Sex differences in treatment and outcome after stroke: Pooled analysis including 19,000 participants. Neurology. 2019. PMID: 31719135. doi:10.1212/WNL.0000000000008615
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。